TIDMPRTC
PureTech Health PLC
12 September 2018
12 September 2018
PureTech Health plc
PureTech's Akili Exclusively In-Licenses Additional Clinical
Stage Digital Technology to Improve Cognitive Function from
University of California San Francisco (UCSF)
Technology Further Builds on Akili's Leading Position in Digital
Therapeutics
PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) Axis, is pleased to note
that Akili Interactive today announced an exclusive license to a
new digital technology that can potentially improve cognitive
function by combining neural targeting with physical activity. The
technology, which is currently being studied in multiple clinical
trials, is delivered through a novel motion-capture video game
experience and holds potential to improve cognitive function in
patients with a wide range of medical conditions.
Eric Elenko, PhD, Chief of Research and Strategy at PureTech
Health, said:
"We're pleased Akili has in-licensed this exciting new
development from the Neuroscape Lab at UCSF and expanded its
collaboration with Adam Gazzaley, MD, PhD, as this technology
further underscores Akili's leading position in the field of
digital medicine. By combining physical activity with technology
that directly engages brain networks associated with cognitive
control, this additional Akili technology has potential to address
a wide range of conditions across neurology and psychology."
Akili's pipeline of product candidates also includes AKL-T01,
which is currently under review with the United States Food and
Drug Administration. AKL-T01 is designed to be prescribed by
physicians as a stand-alone treatment for children and adolescents
with ADHD. If approved, AKL-T01 would be the first prescription
digital treatment for paediatric ADHD.
The full text announcement from Akili is as follows:
Akili Announces Exclusive Licensing Agreement for New Digital
Technology Integrating Neural Systems Targeting and Physical
Activity as Novel Cognitive Dysfunction Treatment Platform
Developed by leading neuroscientists at the UC San Francisco,
currently in multiple clinical trials
Technology is latest in series of new potential digital
treatments Akili is pursuing
BOSTON, September 12, 2018 -- Akili Interactive ("Akili" or
"Company"), a leading prescription digital medicine company
developing novel treatments for cognitive dysfunction and
brain-related conditions, today announced an agreement with the
Regents of the University of California to exclusively license new
digital technology integrating neural systems that target cognitive
function combined with physical activity. The technology is being
studied in multiple clinical trials and holds potential to improve
cognitive function in patients with a wide range of medical
conditions.
The technology was developed at Neuroscape, a research centre
led by Adam Gazzaley, MD, PhD, at UC San Francisco (UCSF), and is
delivered through a novel motion-capture video game interface,
providing an immersive and engaging experience and the ability to
create personalised treatments. The technology is designed to
challenge all three core aspects of cognitive control - attention,
working memory, and cognitive flexibility - while participants
combine cognitive tasks with physical movement.
"The cognitive benefits of physical activity have been
understood for many years. The ability to generate those benefits
through technology that directly engages brain networks associated
with cognitive control is extremely exciting," said Adam Gazzaley,
Founder & Executive Director of Neuroscape and Co-founder and
Chief Scientific Advisor at Akili. "I'm eager to see where Akili's
team of researchers and game creators take this important
technology."
"This technology represents the type of innovation that excites
us at Akili as we look to build our pipeline of novel treatments
for cognitive dysfunction," said Jason Trees, Research and
Development Program Lead for Akili. "We're only just beginning to
scratch the surface of the full potential of digital therapeutics,
and we are continuously looking for the next great innovation that
bridges technology and medicine in ways we can't even imagine
today."
The newly licensed technology represents the latest in a series
of potential new digital medicines Akili is pursuing that directly
target and activate specific neural networks in the brain to treat
psychological and neurological disorders. Both through strategic
licensing and internal discovery efforts, Akili actively seeks out
new innovative technologies with the potential to target specific
brain networks involved in cognitive function. Akili is currently
evaluating several new technologies in numerous clinical studies
across multiple different diseases and disorders where cognitive
function is affected. These early stage programs will fuel Akili's
broad pipeline of programs aimed at treating cognitive deficiency
and improve symptoms associated with medical conditions across
neurology and psychiatry, including attention-deficit/hyperactivity
disorder (ADHD), major depressive disorder (MDD), autism spectrum
disorder (ASD) and various inflammatory diseases. Akili's lead
pipeline program, AKL-T01, is currently under review with the
United States Food and Drug Administration.
This licensing deal was negotiated with UCSF's Office of
Technology Management within Innovation Ventures, which leads
licensing and business development efforts on behalf of the
university.
About Akili
Akili is a prescription digital medicine company combining
scientific and clinical rigor with the ingenuity of the tech
industry to reinvent medicine. Akili is pioneering the development
of digital treatments with direct therapeutic activity, delivered
not through a pill but through a high-quality action video game
experience. Akili is advancing a broad pipeline of programs to
treat cognitive deficiency and improve symptoms associated with
medical conditions across neurology and psychiatry, including ADHD,
MDD, ASD and various inflammatory diseases. Akili is also
developing complementary and integrated clinical monitors and
measurement-based care applications. The Company was founded by
PureTech Health(PRTC.L) and is a founding member of the Digital
Therapeutics Alliance. For more information on Akili, please visit:
www.akiliinteractive.com.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing novel medicines for dysfunctions of the
Brain-Immune-Gut (BIG) Axis. The Company has developed deep
insights into the connection between the individual components of
these systems and the resulting role in many chronic diseases,
which have proven resistant to established therapeutic approaches.
By harnessing this emerging field of human biology, PureTech Health
is developing new categories of medicines with the potential to
have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies across two divisions: the Affiliates division and the
Internal division. Its Affiliates division includes two product
candidates that have been filed with the US Food and Drug
Administration (FDA) for review and several other novel clinical
and pre-clinical programmes. These affiliates are developing
ground-breaking platforms and therapeutic candidates in
collaboration with some of the world's leading experts.
PureTech's Internal division is advancing a pipeline fuelled by
recent discoveries in lymphatics and immune cell trafficking to
modulate disease in a tissue-specific manner. These programmes
leverage the transport and biodistribution of various immune system
components for the targeted treatment of diseases with major unmet
needs, including cancers, autoimmune diseases, and neuroimmune
disorders.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGGUQWBUPRUGP
(END) Dow Jones Newswires
September 12, 2018 07:00 ET (11:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024
